4-Chloro-6-Iodoquinazoline Bulk Price & Manufacturer 2026
Procurement teams and R&D chemists frequently face challenges securing consistent quality for the lapatinib intermediate while managing fluctuating market costs and supply chain disruptions in 2026.
Detailed Chemical Synthesis Route and Reaction Mechanism
The production of 6-iodo-4-chloroquinazoline typically begins with 6-iodo-4(H)-quinazolinone as the primary raw material. The synthesis route involves a chlorination reaction using oxalyl chloride in the presence of anhydrous dimethylformamide (DMF) and 1,2-dichloroethane (DCE). Under nitrogen protection, the mixture is cooled in an ice water bath before the dropwise addition of oxalyl chloride, which generates a Vilsmeier-Haack type reactive intermediate. Following the addition of the quinazolinone substrate, the reaction mixture is heated to reflux for approximately 4.5 hours. This process ensures complete conversion to the target halogenated quinazoline derivative.
Troubleshooting Common Impurities and Yield Issues
Achieving high industrial purity requires strict control over reaction parameters to minimize byproducts that complicate downstream purification.
Managing Residual Starting Material
Incomplete conversion often leads to residual 6-iodo-4(H)-quinazolinone. To mitigate this, manufacturers must ensure precise stoichiometric ratios of oxalyl chloride and maintain adequate reflux times. Analytical monitoring via HPLC during the reaction phase is critical for verifying endpoint completion.
Preventing Di-halogenated Byproducts
Over-chlorination or unintended substitution can occur if temperature controls lapse during the exothermic addition phase. Maintaining strict ice-bath cooling during reagent addition prevents thermal runaway that favors di-halogenated impurities, ensuring the final product meets stringent specifications for kinase inhibitor precursor applications.
Factory-Direct Bulk Pricing Advantages and Supply Chain Stability
As a reliable global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. provides competitive bulk price structures that scale with volume commitments. Unlike trading companies, direct manufacturing allows for rigorous COA verification and traceability for every batch of 4-Chloro-6-iodoquinazoline. Our supply chain is optimized to mitigate logistics delays, ensuring stable inventory levels for long-term production schedules.
Partnering with NINGBO INNO PHARMCHEM CO.,LTD. ensures access to technical support and consistent quality aligned with international pharmacopeia standards.
For custom synthesis requirements or to validate our drop-in replacement data, consult with our process engineers directly.